CMG Pharmaceutical Completes Phase 1 Clinical Trial of Pan TRK Inhibitor Anticancer Drug

[Asia Economy Reporter Gong Byung-sun] CMG Pharmaceutical announced on the 31st that it has completed Phase 1 clinical trials of the Pan TRK inhibitor anticancer drug CHC2014 targeting long-term malignant solid tumors.

As a result of conducting clinical trials on 17 patients with long-term malignant solid tumors, it was found to be safe and well-tolerated. In addition, a dose-dependent pharmacokinetic profile was confirmed, and based on the overall safety results, the recommended dose for Phase 2 was also determined.

CMG Pharmaceutical expects that efficacy will also be demonstrated in the upcoming Phase 2 clinical trials.